Catalent Supporting More than 40 COVID-19 Development Programs!
| |
| Catalent Supporting More than 40 COVID-19 Development Programs! |
|
|
|
|
|
|
| We are working with several customers on multiple COVID-related antivirals, vaccines, diagnostics and treatments for symptoms and effects of COVID-19. This work includes the supporting the delivery of over 2 million COVID-19 test kits monthly. Please contact us to learn how we can help accelerate your projects to patients. |
|
|
|
| | |
|
|
| |
| |
| Johnson & Johnson Partners with Catalent to Manufacture Lead COVID-19 Vaccine Candidate
The collaboration commits joint investment to accelerate rapid scale-up and segregated cGMP commercial manufacturing capacity at Catalent’s facility in Bloomington, Indiana over the coming months to support dedicated production of Johnson & Johnson’s investigational vaccine candidate. Starting in July, Catalent plans to hire 300 employees at the site for this program, so that it can meet operational readiness and 24×7 manufacturing schedules by January 2021.
Catalent’s Bloomington facility was recently showcased in ABC News Nightline TV news magazine, the Catalent story begins at 4:50. |
|
|
|
|
|
|
| |
| |
| Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
The partnership supports the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus. Manufacturing of LUNAR-COV19 will take place at Catalent’s facility in Madison, Wisconsin to initially support human clinical studies and, if successful, commercialization of the vaccine. Manufacturing will take advantage of the facility’s flex-suite, a cGMP bioprocessing suite that can produce batches at multiple scales and support Arcturus’ proprietary mRNA manufacturing process.
Arcturus Therapeutics’ CEO, Joe Payne, was recently interviewed on CNN and mentioned our great partnership, view the clip below. |
|
|
|
|
|
|
| |
| |
| |
| |
| |
| Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19
Catalent also welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. |
|
|
|
|
|
|
| |
| | | Catalent Announces Acquisition of Japanese Facility to Provide Local and Global Clinical Supply Solutions
Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals. This purchase will establish a new clinical GMP manufacturing and distribution hub to support clinical studies. The 60,000-square-foot facility will be the largest in the company’s Asia Pacific clinical supply network. |
|
|
|
|
|
|
| |
| |
| Triphase Accelerator and Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Non-Hodgkin’s Lymphoma
Triphase Accelerator and Catalent announced interim results for Triphase Accelerator’s multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma.
TRPH-222 was originally developed by Catalent’s subsidiary Redwood Bioscience, Inc., using its proprietary SMARTag® platform, which provides optimized site-specific protein-modification and linker technologies. Read about our recent webinar with Triphase later in this newsletter. |
|
|
|
|
|
|
| |
| Join Our Experts at Virtual Live Events and hear the Latest on Covid-19 and Technology Developments |
| | Catalent’s participation at live events has either been postponed or cancelled due to the COVID-19 pandemic. Stay current on all the latest solutions needed to advance your projects with our webinars and virtual events.
Webinar | The Outlook for Cancer Gene Therapies | June 1
What hurdles need to be overcome before gene therapy is a major new modality in the cancer therapy arsenal? During this webinar Catalent's Thomas VanCott, Ph.D., and other industry experts will discuss manufacturing, viral vectors, and consider the most promising approaches coming to the clinic.
BIO Digital (Virtual Conference) | June 8-12
On June 8, Catalent’s Julien Meissonnier, Vice President and Chief Scientific Officer, will present Technology Integrators in Cell and Gene Therapy: Increased Efficiency and Standardization. He will discuss strategies for alleviating manufacturing bottlenecks to help achieve more optimized and reproducible manufacturing processes.
On June 9, join Catalent’s Chair & Chief Executive Officer, John Chiminski when he will join other top R&D executives for a panel discussing R&D Leadership During the Pandemic, as part of Endpoints at BIO. Register for this free, dynamic panel discussion. Registration is complimentary.
On June 10, Catalent Biologics’ Gregory Bleck, Ph.D., Global Head of R&D, will present GPEx® Boost: A Novel Approach for High-Expressing CHO Cell Line Engineering, where he will describe GPEx Boost technology in more detail and discuss additional case study comparisons. |
|
|
|
|
|
|
| A Catalyst in Drug Development |
|
|
|
|
|
|
| Kirk Reynolds, Ph.D. Scientist, Injectable Formulation Development, Catalent San Diego |
|
|
|
|
|
|
| Kirk Reynolds, Ph.D. is a Scientist, for Injectable Formulation Development, at Catalent’s San Diego, California Facility. As a formulation scientist, Dr. Reynolds specializes in early phase formulation development for parenteral products that are just coming out of discovery. He also works on projects in pre-clinical and early phase development of the latest therapies across a broad range of injectable delivery routes. Discover what drives his passion for injectable formulation development, read his published works that include 4 peer-reviewed articles. |
|
|
|
| | |
|
|
| |
| |
| BIOLOGICS
- Article: “Avoiding Delays on the Pathway to Clinic” - How can developers ensure they get to the clinic as efficiently and smoothly as possible? In this Q&A article, a Catalent Biologics expert discusses issues that could delay the time to clinic and the ways to avoid them.
- Article: “Gene Therapy – Unprecedented Growth and Challenges” - Achieving Faster Timelines and Higher Titer in Antibody Expression Gene therapy is a rapidly growing area in healthcare but now that the promise has been shown, we must focus on improving the manufacturing process and reducing costs. Read this article by Philip Wills, Ph.D., at Catalent Cell & Gene Therapy to get expert insight on trends in gene therapy, growth drivers and strategies to overcome manufacturing challenges.
- Webinar: “Drug Manufacturing in a Time of Coronavirus” - This is an unprecedented time and we must work together to find innovative solutions at warp speed to beat COVID-19 and save lives. John Carroll from Endpoints moderates a discussion between experts from Moderna, Sanofi Pasteur, Takeda and Catalent.
|
|
|
|
| | |
|
|
| CLINICAL SUPPLY SERVICES
|
|
|
|
| | |
|
|
| ORAL DRUG DELIVERY
- Executive Summary: “Strategies for Flexible Manufacturing” - Download this executive summary for an in-depth look at flexible manufacturing including the latest market drivers, approaches, and technology.
- Article: “Placing Patients at the Center of Drug Design” - Poor patient acceptance and adherence to medication continue to be key challenges facing the healthcare and pharmaceutical industries. Learn strategies for formulation and dosage forms that developers can use to bring patient insights into the design of their drug products.
- Video: “Zydis® Fast Disintegrating Technology – Best-in-Class for Better Outcomes” - The Zydis orally disintegrating tablet is a unique, freeze-dried oral solid dosage form that disperses almost instantly in the mouth – no water required. It is an ideal technology for pediatrics, geriatrics and those with difficulty swallowing. It also helps improve compliance, and offers market differentiation.
- Article: “A Changing Landscape” - As the pharmaceutical industry has evolved and grown, so too has its ability to develop child-friendly formulations. In this article Catalent’s Andrew Parker, Ph.D. Director Open Innovation, discusses how the industry has changed to make pediatric formulations a priority and Matt Ling Ph.D. Director, Scientific Services discusses key challenges in development.
|
|
|
|
| | |
|
|
| CONSUMER HEALTH
- Executive Summary: “EPA/DHA Omega-3s: Trends and Opportunities for 2020” – In this summary, hear from GOED and Catalent on opportunities to incorporate Omega-3’s into new formulations that have strong scientific evidence to show they support specific health needs.
- Infographic: “Innovation in OTC Products – A Survey Report on Why It Matters and How to Achieve It” - Catalent and FiercePharma conducted a survey which generated responses from the OTC industry. Download this infographic to learn more about survey results and expert insight on trends uncovered by the survey.
- Webinar: “The Rise of Beauty Nutrition” - The conventional beauty industry is focused on aesthetics, while the nutritional industry focuses on wellbeing. As these massive markets overlap, there is an opportunity for a broader range of solutions, products, and technologies to meet consumer expectations and advantages of combining these two perspectives.
|
|
|
|
| | |
|
|
| |
| Join a leader making a difference in today’s world. Our teams are rapidly growing in the following areas:
- Baltimore, Maryland
- Bloomington, Indiana
- Madison, Wisconsin
- St. Petersburg, Florida
We have open positions in multiple other locations, as well. Apply today!
View our openings in product development. |
|
|
|
| | |
|
|
| |
| Every brand has a challenge. We have a solution. |
| | | | or call +1 877 891 9609 to speak with one of our experts today! |
| | |
|
|
|
|
|
| |
 |
